TGFB1 and metabolic dysfunction-associated steatohepatitis: In comparison to NASH control: hAEC-CM:- Increased MMP-9 expressionAll treatments:- Reduced liver fibrosis area.- Reduced pSMAD 2/3 signaling (TGF-β1 signaling pathway)- Reduced activated hepatic stellate cells and liver macrophages.